No Loading Dose Required After Two-Week Interruption
Rivaroxaban does not require a loading dose when restarting after a two-week interruption—simply resume at the standard therapeutic dose appropriate for the indication.
Rationale Based on Pharmacokinetics
Rivaroxaban has a short half-life of 8-9 hours 1, meaning the drug is completely eliminated from the body within approximately 2-3 days after discontinuation (approximately 4-5 half-lives). After a two-week interruption, there is zero residual anticoagulant effect, and the patient's coagulation system has returned to baseline.
The concept of a "loading dose" is fundamentally unnecessary for rivaroxaban because:
- The drug reaches steady-state concentrations within 2-3 days of regular dosing
- Therapeutic anticoagulation is achieved within hours of the first dose
- Unlike warfarin, there is no delayed onset requiring bridging or loading strategies
Standard Resumption Protocol
When restarting rivaroxaban after any interruption (whether 2 days or 2 weeks):
For atrial fibrillation:
- Resume at 20 mg once daily (or 15 mg once daily if creatinine clearance 30-49 mL/min) 2
- No bridging with parenteral anticoagulation needed 3
For VTE treatment:
- If the patient was in the initial treatment phase (first 21 days), resume the higher dose: 15 mg twice daily for the remainder of the 21-day period, then transition to 20 mg once daily 3
- If the patient was already on maintenance therapy (20 mg once daily), simply resume at 20 mg once daily
Context: Perioperative Management vs. Non-Adherence
The available guidelines address perioperative interruption scenarios where rivaroxaban is intentionally stopped for surgery 1, 3, 2. In these contexts:
- Low bleeding risk procedures: Resume full therapeutic dose 24 hours post-procedure 1
- High bleeding risk procedures: May use reduced dose (10 mg once daily) for 2-3 days, then increase to therapeutic dose 1
However, this graduated approach is specific to the immediate post-surgical bleeding risk, not because of any pharmacokinetic need for dose titration after drug interruption.
Important Caveats
Assess thrombotic risk during the gap period: A two-week interruption represents significant time without anticoagulation. Consider whether:
- The patient experienced any thromboembolic events during the interruption
- The underlying indication still exists and is appropriately managed
- Any bridging anticoagulation should have been used (though this is retrospective)
Evaluate bleeding risk factors: Before restarting, ensure:
- No active bleeding or recent major bleeding events
- Renal function is stable (rivaroxaban is 33% renally cleared) 1
- No new drug interactions with strong CYP3A4 or P-glycoprotein inhibitors 4
The 2022 CHEST guidelines 2 explicitly state that the rapid offset and rapid onset of action of DOACs obviate the need for heparin bridging, which by extension means no loading strategies are needed when restarting therapy after interruption.
Clinical Bottom Line
Resume rivaroxaban at the standard therapeutic dose for the indication. The two-week gap is irrelevant to dosing strategy—treat it as initiating therapy in a treatment-naive patient, using the standard dosing regimen without any loading phase.